Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2006

Open Access 01-12-2006 | Original investigation

Interaction of obesity, metabolic syndrome and Framingham risk on steatohepatitis among healthy Taiwanese: population-based nested case-control study

Authors: Kuo-Liong Chien, Hsiu-Ching Hsu, Chia-Lun Chao, Bai-Chin Lee, Ming-Fong Chen, Yuan-Teh Lee

Published in: Cardiovascular Diabetology | Issue 1/2006

Login to get access

Abstract

Background

There have been scant reports on the cumulative effects of atherosclerotic risk factors on steatohepatitis.

Methods

We defined cases of steatohepatitis (n = 124) from one health examination center at National Taiwan University Hospital from January to December 2002. We selected controls, matched by age, gender and drinking status. Metabolic syndrome was defined by the modified ATP-III guidelines. High-dimensional interactions of risk factors for steatohepatitis were evaluated.

Results

Steatohepatitis cases had the highest C-reactive protein, lymphocytes, Framingham scores and predicted coronary risks. The odds ratio (OR) of metabolic syndrome for steatohepatitis was the highest (OR = 9.9), followed by high glucose status (OR = 4.5) and obesity (OR = 3.6). The highest area under the ROC curve was metabolic syndrome (area = 0.80), followed by obesity (0.75) and high glucose level (0.73). Metabolic syndrome was the highest population-attributable risk factor (0.59). Significant interaction was found with a three-factor model, including obesity, metabolic syndrome and Framingham risk status, with lesser average prediction error (22.6%), higher average cross-validation consistency (6.3) and lower average prediction error (24.3%). Compared with persons with no risk factors, OR increased as the number of risk factors increased (OR = 3.0 with one risk factor, 17.5 with two risk factors, 10.8 with three risk factors, respectively).

Conclusion

Metabolic syndrome, inflammation markers and atherosclerotic risk scores are significantly related to steatohepatitis status among the healthy examinee population in Taiwan.
Appendix
Available only for authorised users
Literature
1.
go back to reference Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ: Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis. 2001, 21: 17-26. 10.1055/s-2001-12926.CrossRefPubMed Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ: Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis. 2001, 21: 17-26. 10.1055/s-2001-12926.CrossRefPubMed
2.
go back to reference Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G: Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev. 2004, 5: 27-42. 10.1111/j.1467-789X.2004.00126.x.CrossRefPubMed Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G: Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev. 2004, 5: 27-42. 10.1111/j.1467-789X.2004.00126.x.CrossRefPubMed
3.
go back to reference Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S: Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003, 38: 954-961. 10.1007/s00535-003-1178-8.CrossRefPubMed Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S: Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003, 38: 954-961. 10.1007/s00535-003-1178-8.CrossRefPubMed
4.
go back to reference Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001, 50: 1844-1850.CrossRefPubMed Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001, 50: 1844-1850.CrossRefPubMed
5.
go back to reference Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N: Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999, 107: 450-455. 10.1016/S0002-9343(99)00271-5.CrossRefPubMed Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N: Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999, 107: 450-455. 10.1016/S0002-9343(99)00271-5.CrossRefPubMed
6.
go back to reference Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M: Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002, 35: 367-372. 10.1053/jhep.2002.30690.CrossRefPubMed Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M: Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002, 35: 367-372. 10.1053/jhep.2002.30690.CrossRefPubMed
7.
go back to reference Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003, 37: 917-923. 10.1053/jhep.2003.50161.CrossRefPubMed Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003, 37: 917-923. 10.1053/jhep.2003.50161.CrossRefPubMed
8.
go back to reference Shen YH, Yang WS, Lee TH, Lee LT, Chen CY, Huang KC: Bright liver and alanine aminotransferase are associated with metabolic syndrome in adults. Obes Res. 2005, 13: 1238-1245.CrossRefPubMed Shen YH, Yang WS, Lee TH, Lee LT, Chen CY, Huang KC: Bright liver and alanine aminotransferase are associated with metabolic syndrome in adults. Obes Res. 2005, 13: 1238-1245.CrossRefPubMed
9.
go back to reference Chien KL, Hsu HC, Su TC, Lee YT: Consistency in genetic inheritance mode and heritability patterns of triglyceride vs. high density lipoprotein cholesterol ratio in two Taiwanese family samples. BMC Journal Genetics. 2003, 4: 7-16. 10.1186/1471-2156-4-7.CrossRefPubMed Chien KL, Hsu HC, Su TC, Lee YT: Consistency in genetic inheritance mode and heritability patterns of triglyceride vs. high density lipoprotein cholesterol ratio in two Taiwanese family samples. BMC Journal Genetics. 2003, 4: 7-16. 10.1186/1471-2156-4-7.CrossRefPubMed
10.
go back to reference Lopes-Virella M, Stone P, Ellis S, Colwell JA: Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem. 1977, 23: 882-884.PubMed Lopes-Virella M, Stone P, Ellis S, Colwell JA: Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem. 1977, 23: 882-884.PubMed
11.
go back to reference Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18: 499-502.PubMed Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18: 499-502.PubMed
12.
go back to reference Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001, 285: 2486-2497. 10.1001/jama.285.19.2486. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001, 285: 2486-2497. 10.1001/jama.285.19.2486.
13.
go back to reference Tan CE, Ma S, Wai D, Chew SK, Tai ES: Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?. Diabetes Care. 2004, 27: 1182-1186.CrossRefPubMed Tan CE, Ma S, Wai D, Chew SK, Tai ES: Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?. Diabetes Care. 2004, 27: 1182-1186.CrossRefPubMed
14.
go back to reference WHO expert consultation: Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004, 363: 157-163. 10.1016/S0140-6736(03)15268-3.CrossRef WHO expert consultation: Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004, 363: 157-163. 10.1016/S0140-6736(03)15268-3.CrossRef
15.
go back to reference Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982, 143: 29-36.CrossRefPubMed Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982, 143: 29-36.CrossRefPubMed
16.
go back to reference Rothman KJ, Greenland S: Modern Epidemiology. 1998, Philadelphia, Lippincott-Raven Publisher, second Rothman KJ, Greenland S: Modern Epidemiology. 1998, Philadelphia, Lippincott-Raven Publisher, second
17.
go back to reference Hosmer DW, Lemeshow S: Applied logistic regression. 1989, New York: John Wiley & Sons Hosmer DW, Lemeshow S: Applied logistic regression. 1989, New York: John Wiley & Sons
18.
go back to reference Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, Moore JH: Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet. 2001, 69: 138-147. 10.1086/321276.PubMedCentralCrossRefPubMed Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, Moore JH: Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet. 2001, 69: 138-147. 10.1086/321276.PubMedCentralCrossRefPubMed
19.
go back to reference Hahn L, Ritchie M, Moore J: Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics. 2003, 19: 376-382. 10.1093/bioinformatics/btf869.CrossRefPubMed Hahn L, Ritchie M, Moore J: Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics. 2003, 19: 376-382. 10.1093/bioinformatics/btf869.CrossRefPubMed
20.
go back to reference Farrell GC: Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?. J Gastroenterol Hepatol. 2003, 18: 124-138. 10.1046/j.1440-1746.2003.02989.x.CrossRefPubMed Farrell GC: Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?. J Gastroenterol Hepatol. 2003, 18: 124-138. 10.1046/j.1440-1746.2003.02989.x.CrossRefPubMed
21.
go back to reference Shen YH, Yang WS, Lee TH, Lee LT, Chen CY, Huang KC: Bright liver and alanine aminotransferase are associated with metabolic syndrome in adults. Obes Res. 2005, 13: 1238-1245.CrossRefPubMed Shen YH, Yang WS, Lee TH, Lee LT, Chen CY, Huang KC: Bright liver and alanine aminotransferase are associated with metabolic syndrome in adults. Obes Res. 2005, 13: 1238-1245.CrossRefPubMed
22.
go back to reference Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG: Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999, 84: 1513-1517. 10.1210/jc.84.5.1513.CrossRefPubMed Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG: Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999, 84: 1513-1517. 10.1210/jc.84.5.1513.CrossRefPubMed
23.
go back to reference Huang KC, Lin WY, Lee LT, Chen CY, Lo H, Hsia HH, Liu IL, Shau WY, Lin RS: Four anthropometric indices and cardiovascular risk factors in Taiwan. Int J Obes Relat Metab Disord. 2002, 26: 1060-1068. 10.1038/sj.ijo.0802047.CrossRefPubMed Huang KC, Lin WY, Lee LT, Chen CY, Lo H, Hsia HH, Liu IL, Shau WY, Lin RS: Four anthropometric indices and cardiovascular risk factors in Taiwan. Int J Obes Relat Metab Disord. 2002, 26: 1060-1068. 10.1038/sj.ijo.0802047.CrossRefPubMed
24.
go back to reference Lin WY, Lee LT, Chen CY, Lo H, Hsia HH, Liu IL, Lin RS, Shau WY, Huang KC: Optimal cut-off values for obesity: using simple anthropometric indices to predict cardiovascular risk factors in Taiwan. Int J Obes Relat Metab Disord. 2002, 26: 1232-1238. 10.1038/sj.ijo.0802040.CrossRefPubMed Lin WY, Lee LT, Chen CY, Lo H, Hsia HH, Liu IL, Lin RS, Shau WY, Huang KC: Optimal cut-off values for obesity: using simple anthropometric indices to predict cardiovascular risk factors in Taiwan. Int J Obes Relat Metab Disord. 2002, 26: 1232-1238. 10.1038/sj.ijo.0802040.CrossRefPubMed
25.
go back to reference Pereira JA, Lazarin MA, Pareja JC, de SA, Muscelli E: Insulin resistance in nondiabetic morbidly obese patients: effect of bariatric surgery. Obes Res. 2003, 11: 1495-1501.CrossRefPubMed Pereira JA, Lazarin MA, Pareja JC, de SA, Muscelli E: Insulin resistance in nondiabetic morbidly obese patients: effect of bariatric surgery. Obes Res. 2003, 11: 1495-1501.CrossRefPubMed
Metadata
Title
Interaction of obesity, metabolic syndrome and Framingham risk on steatohepatitis among healthy Taiwanese: population-based nested case-control study
Authors
Kuo-Liong Chien
Hsiu-Ching Hsu
Chia-Lun Chao
Bai-Chin Lee
Ming-Fong Chen
Yuan-Teh Lee
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2006
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-5-12

Other articles of this Issue 1/2006

Cardiovascular Diabetology 1/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.